Clinical Trial Update: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses the combination of pozelimab and cemdisiran in adults with paroxysmal nocturnal hemoglobinuria who switched from eculizumab, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2025-06-25